LFM-A13 is a highly selective inhibitor of the non-receptor tyrosine kinase BTK (Brutons tyrosine kinase) (IC50 = 2.5 µM). It irreversibly severs the downstream signaling network of the B-cell receptor (BCR) by targeted binding to the BTK kinase catalytic domain, exhibiting excellent anti-leukemic and immunomodulatory effects in models of acute/chronic lymphocytic leukemia and severe autoimmune diseases.
Molekulargewicht:
360
Reinheit:
99.50%
CAS Nummer:
[62004-35-7]
Formel:
C11H8Br2N2O2
Target-Kategorie:
BTK
T212732
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
